Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RPTP Raptor Pharmaceutical Corp. (MM)

0.00 (0.00%)
Jun 13 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 0
Bid Price 5.10
Ask Price 9.00
News -
Company Name Stock Ticker Symbol Market Type
Raptor Pharmaceutical Corp. (MM) RPTP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 9.00 20:00:00
Open Price Low Price High Price Close Price Prev Close
9.00 9.00
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 9.00 USD

Raptor Pharmaceutical Corp. (MM) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 767.76M - - - -9.45
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Raptor Pharmaceutical Corp. (MM) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No RPTP Message Board. Create One! See More Posts on RPTP Message Board See More Message Board Posts

Historical RPTP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year0.
3 Years0.
5 Years0.

Raptor Pharmaceutical Corp. (MM) Description

Raptor Pharmaceutical Corp was initially incorporated in Nevada on July 29, 1997 as Axonyx Inc. In October 2006, Axonyx Inc. and its then wholly-owned subsidiary completed a reverse merger, business combination with TorreyPines Therapeutics, Inc., reincorporated in Delaware and changed the corporate name to 'TorreyPines Therapeutics, Inc. On September 28, 2009, the Company name was again changed from TorreyPines Therapeutics, Inc., to Raptor Pharmaceutical Corp. It is a biopharmaceutical company focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company's product PROCYSBI cysteamine bitartrate, delayed-release capsules received marketing approval from the U.S. Food and Drug Administration on April 30, 2013 for the management of nephropathic cystinosis in adults and children six years and older.

Your Recent History

Delayed Upgrade Clock